|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US20150017136A1
(en)
*
|
2013-07-15 |
2015-01-15 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotherapy
|
|
US20230050345A1
(en)
*
|
2013-05-13 |
2023-02-16 |
Cellectis |
Methods for engineering allogeneic and highly active t cell for immunotheraphy
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
KR20230054509A
(ko)
|
2013-11-07 |
2023-04-24 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
|
AU2014351871B2
(en)
*
|
2013-11-22 |
2020-02-13 |
Cellectis |
Method for generating batches of allogeneic T-cells with averaged potency
|
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
|
AU2014368383B2
(en)
*
|
2013-12-20 |
2020-01-16 |
Cellectis |
Method of engineering multi-input signal sensitive T cell for immunotherapy
|
|
ES2740903T3
(es)
|
2014-03-19 |
2020-02-07 |
Cellectis |
Receptores antigénicos quiméricos específicos de CD123 para inmunoterapia del cáncer
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
EP4427809A3
(en)
|
2014-10-31 |
2024-12-04 |
The Trustees of The University of Pennsylvania |
Altering gene expression in car-t cells and uses thereof
|
|
CA2973529A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
AU2016214301B2
(en)
*
|
2015-02-06 |
2022-05-19 |
Cellectis |
Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
|
|
US11186824B2
(en)
|
2015-03-11 |
2021-11-30 |
Cellectis |
Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
|
|
BR112017020750A2
(pt)
*
|
2015-03-27 |
2018-06-26 |
Harvard College |
células t modificadas e métodos de produção e utilização das mesmas
|
|
JP6921001B2
(ja)
|
2015-04-13 |
2021-08-18 |
ファイザー・インク |
Ｂ細胞成熟抗原を標的にするキメラ抗原受容体
|
|
US10441644B2
(en)
|
2015-05-05 |
2019-10-15 |
The Regents Of The University Of California |
H3.3 CTL peptides and uses thereof
|
|
HK1254190A1
(zh)
|
2015-05-08 |
2019-07-12 |
President And Fellows Of Harvard College |
通用供体干细胞和相关方法
|
|
WO2016196388A1
(en)
*
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
US20180171298A1
(en)
*
|
2015-06-30 |
2018-06-21 |
Cellectis |
Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
|
|
GB2557123B
(en)
|
2015-07-31 |
2021-11-03 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
US12043852B2
(en)
|
2015-10-23 |
2024-07-23 |
President And Fellows Of Harvard College |
Evolved Cas9 proteins for gene editing
|
|
JP2018536436A
(ja)
|
2015-12-04 |
2018-12-13 |
ノバルティス アーゲー |
免疫腫瘍学のための組成物および方法
|
|
ES2983043T3
(es)
*
|
2015-12-18 |
2024-10-21 |
Sangamo Therapeutics Inc |
Alteración dirigida del receptor de células T
|
|
US10259876B2
(en)
|
2016-01-21 |
2019-04-16 |
Pfizer Inc. |
Chimeric antigen receptors targeting epidermal growth factor receptor variant III
|
|
EP3429633B1
(en)
|
2016-04-15 |
2021-02-24 |
Cellectis |
A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
|
US20190262398A1
(en)
*
|
2016-08-23 |
2019-08-29 |
Bluebird Bio, Inc. |
Tim3 homing endonuclease variants, compositions, and methods of use
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
IL265045B2
(en)
*
|
2016-09-08 |
2023-09-01 |
Bluebird Bio Inc |
Variants of endonuclease pd-1, compositions and methods of use
|
|
MA46236A
(fr)
|
2016-09-14 |
2019-07-24 |
Janssen Biotech Inc |
Récepteurs antigéniques chimériques comprenant des domaines de la fibronectine de type iii spécifiques du bcma, et utilisations correspondantes
|
|
CA3039797A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Minerva Biotechnologies Corporation |
Humanized anti-muc1* antibodies and use of cleavage enzyme
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
WO2018073393A2
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
|
|
US11261428B2
(en)
|
2018-03-15 |
2022-03-01 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
AU2018221730B2
(en)
|
2017-02-15 |
2024-06-20 |
Novo Nordisk A/S |
Donor repair templates multiplex genome editing
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
KR20190127797A
(ko)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
시토신에서 구아닌으로의 염기 편집제
|
|
MX2019011272A
(es)
|
2017-03-22 |
2019-10-24 |
Novartis Ag |
Composiciones y metodos para inmunooncologia.
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
MY201327A
(en)
|
2017-06-02 |
2024-02-16 |
Pfizer |
Chimeric antigen receptors targeting flt3
|
|
KR20200019231A
(ko)
*
|
2017-06-22 |
2020-02-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
조절 면역 세포를 제조하기 위한 방법 및 이의 용도
|
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
JP2020530277A
(ja)
|
2017-06-30 |
2020-10-22 |
セレクティスＣｅｌｌｅｃｔｉｓ |
反復投与のための細胞免疫療法
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
CA3070100A1
(en)
|
2017-07-17 |
2019-01-24 |
Janssen Biotech, Inc. |
Antigen binding regions against fibronectin type iii domains and methods of using the same
|
|
AU2018303686B2
(en)
*
|
2017-07-21 |
2025-04-03 |
Cellectis |
Engineered immune cells resistant to tumor microoenvironment
|
|
WO2019016360A1
(en)
|
2017-07-21 |
2019-01-24 |
Cellectis |
MODIFIED IMMUNE CELLS RESISTANT TO TUMOR MICRO-ENVIRONMENT
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
CA3079652C
(en)
*
|
2017-10-20 |
2022-07-19 |
Pharmabcine Inc. |
Anti-vista antibody and use thereof
|
|
AU2018359532C9
(en)
|
2017-11-01 |
2025-02-13 |
Allogene Therapeutics, Inc. |
Modified caspase-9 polypeptides and methods of use thereof
|
|
CN111556893A
(zh)
*
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
WO2019126555A1
(en)
*
|
2017-12-20 |
2019-06-27 |
Bluebird Bio, Inc. |
Ctla4 homing endonuclease variants, compositions, and methods of use
|
|
WO2019129850A1
(en)
|
2017-12-29 |
2019-07-04 |
Cellectis |
Off-the-shelf engineered cells for therapy
|
|
CN112020518A
(zh)
|
2018-02-01 |
2020-12-01 |
辉瑞公司 |
靶向cd70的嵌合抗原受体
|
|
PE20251579A1
(es)
|
2018-02-01 |
2025-06-16 |
Pfizer |
Anticuerpos especificos para cd70 y sus usos
|
|
KR20200128116A
(ko)
|
2018-02-28 |
2020-11-11 |
화이자 인코포레이티드 |
Il-15 변이체 및 이의 용도
|
|
BR112020018658A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imu-noterapia aprimorada
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
US20210268028A1
(en)
|
2018-07-02 |
2021-09-02 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
|
AU2019327913A1
(en)
|
2018-08-29 |
2021-03-18 |
Nanjing Legend Biotech Co., Ltd. |
Anti-mesothelin chimeric antigen receptor (CAR) constructs and uses thereof
|
|
WO2020051562A2
(en)
|
2018-09-07 |
2020-03-12 |
Beam Therapeutics Inc. |
Compositions and methods for improving base editing
|
|
EP3847196A4
(en)
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
CN112654245B
(zh)
*
|
2018-09-11 |
2022-05-27 |
得克萨斯州大学系统董事会 |
自身免疫不良事件和免疫检查点阻断治疗的遗传小鼠模型
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
US20200268797A1
(en)
|
2018-11-30 |
2020-08-27 |
Janssen Biotech, Inc. |
Gamma delta t cells and uses thereof
|
|
KR20210102925A
(ko)
|
2018-12-10 |
2021-08-20 |
블루버드 바이오, 인코포레이티드. |
호밍 엔도뉴클레아제 변이체
|
|
WO2020132810A1
(en)
*
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
MX2021009357A
(es)
*
|
2019-02-04 |
2021-11-17 |
Ksq Therapeutics Inc |
Dianas de genes de combinacion para mejorar la inmunoterapia.
|
|
EP3693974A1
(en)
*
|
2019-02-07 |
2020-08-12 |
Koninklijke Philips N.V. |
Identifying responsiveness to radio-immuno combination therapy
|
|
DE112020001306T5
(de)
|
2019-03-19 |
2022-01-27 |
Massachusetts Institute Of Technology |
Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
JP2022546364A
(ja)
|
2019-08-27 |
2022-11-04 |
ヤンセン バイオテツク，インコーポレーテツド |
キメラ抗原受容体系及びその使用
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
WO2021176373A1
(en)
|
2020-03-03 |
2021-09-10 |
Janssen Biotech, Inc. |
ꝩδ T CELLS AND USES THEREOF
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート，インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
|
AU2021312871A1
(en)
|
2020-07-21 |
2023-02-09 |
Allogene Therapeutics, Inc. |
Chimeric antigen receptors with enhanced signaling and activities and uses thereof
|
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
EP4313122A1
(en)
|
2021-03-23 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2023057285A1
(en)
|
2021-10-06 |
2023-04-13 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
EP4502177A1
(en)
|
2022-03-24 |
2025-02-05 |
Nanjing Legend Biotech Co., Ltd. |
Method for preparing dna library and detecting retroviral integration site
|
|
EP4504764A1
(en)
|
2022-05-26 |
2025-02-12 |
Caribou Biosciences, Inc. |
Cytokine-receptor fusions for immune cell stimulation
|
|
KR20250020432A
(ko)
|
2022-06-06 |
2025-02-11 |
카리부 바이오사이언시스 인코포레이티드 |
조작 면역 세포를 이용한 자가면역 질환의 치료
|
|
CA3267168A1
(en)
|
2022-09-09 |
2024-03-14 |
Rongsu Qi |
PROCESSES FOR GENERING TIL PRODUCTS USING DOUBLE INACTIVATION OF TALEN PD-1/TIGIT
|
|
CA3267183A1
(en)
|
2022-09-09 |
2024-03-14 |
Hequn Yin |
PROCESSES FOR GENERING TIL PRODUCTS USING DOUBLE TALEN INACTIVATION OF PD-1/TIGIT
|
|
EP4608979A1
(en)
*
|
2022-10-28 |
2025-09-03 |
CorrectSequence Therapeutics (Shanghai) Co., Ltd |
Gene editing systems and methods for reducing immunogenicity and graft versus host response
|
|
EP4584283A1
(en)
|
2022-11-14 |
2025-07-16 |
Caribou Biosciences, Inc. |
Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
|
|
KR20240076377A
(ko)
|
2022-11-23 |
2024-05-30 |
가톨릭대학교 산학협력단 |
인간 혈청 알부민을 이용한 면역억제 t 세포의 대량 생산 방법
|
|
KR20250152085A
(ko)
|
2023-05-01 |
2025-10-22 |
카리부 바이오사이언시스 인코포레이티드 |
Bcma-표적화 조작된 면역 세포를 이용한 자가면역 질환의 치료
|
|
WO2025171182A1
(en)
|
2024-02-08 |
2025-08-14 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with cancer vaccine
|
|
WO2025193386A1
(en)
|
2024-03-13 |
2025-09-18 |
Caribou Biosciences, Inc. |
Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells
|